latest news in companies
Anthropic and HealthEx Partner to Bring AI Analysis to Personal Medical Records
San Francisco, Sunday, 11 January 2026.
Anthropic’s new partnership with HealthEx allows users to securely analyze personal data from over 50,000 healthcare providers, transforming scattered records into actionable insights via private AI conversations.
Fox Sports Reschedules IndyCar Ad Debut for NFL Divisional Playoffs
Los Angeles, Sunday, 11 January 2026.
Fox Sports has strategically adjusted the launch of its marquee IndyCar promotional campaign, moving the debut from the NFL Wild Card weekend to the Divisional Round games scheduled for the weekend of January 17, 2026. While initial industry reports anticipated a launch during the January 10-11 matchups, the network—a subsidiary of Fox Corporation (FOXA)—opted to delay the driver-focused commercials. This scheduling shift positions the racing series’ exposure alongside higher-stakes NFL content, potentially maximizing viewer engagement during a more decisive phase of the playoffs. The revised timeline underscores the network’s calculated approach to leveraging its premium football broadcasting rights to effectively cross-promote the IndyCar property to a broader sports audience.
Allegiant Acquires Sun Country in $1.5 Billion Deal to Reshape Budget Travel
Minneapolis, Sunday, 11 January 2026.
Allegiant’s $1.5 billion acquisition of Sun Country marks a pivotal consolidation in the budget carrier market. The deal promises a nearly 20% premium for shareholders and creates a leisure powerhouse serving 22 million annual passengers.
Molecular Partners Launches Clinical Trial for New Radioactive Cancer Treatment
San Francisco, Sunday, 11 January 2026.
The biotech firm has initiated a Phase 1/2a study for its lead Radio-DARPin candidate, MP0712, confirming operations are funded through 2028 with initial trial data expected this year.
Krystal Biotech Forecasts Strong Fourth Quarter Revenue as Rare Disease Pipeline Expands
San Francisco, Sunday, 11 January 2026.
Krystal Biotech projects $107 million in quarterly revenue and holds $955 million in cash, financing a strategic expansion following a breakthrough in its cystic fibrosis gene therapy program.
